Gain Therapeutics (NASDAQ:GANX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $2.75 target price on the stock. Zacks Investment Research‘s price target indicates a potential upside of 3.77% from the stock’s previous […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) CEO Eric I. Richman acquired 4,000 shares of the business’s stock in a transaction on Thursday, May 19th. The shares were purchased at an average cost of $2.71 per share, for a total transaction of $10,840.00. Following the completion of the acquisition, the chief executive officer now directly […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) was the target of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 30,800 shares, a decline of 17.9% from the February 28th total of 37,500 shares. Approximately 0.4% of the shares of the company are sold […]
Gain Therapeutics (NASDAQ:GANX – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.16, Fidelity Earnings reports. Gain Therapeutics had a negative return on equity of 33.77% and a negative net margin of 8,470.12%. Shares of […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 37,500 shares, a decline of 42.0% from the February 13th total of 64,700 shares. Based on an average trading volume of 55,100 shares, the days-to-cover ratio is […]